Clinical Labs Reject Standard Trend Lines to Prevent Attenuation Bias in Blood Tests

Clinical laboratories validating new diagnostic machines no longer rely on the standard trend lines taught in introductory statistics. When a hospital upgrades a blood glucose or troponin analyzer, assuming the old reference machine was perfectly accurate mathematically guarantees the new device will look flawed.[1]

This mathematical trap is known as attenuation bias. Ordinary Least Squares regression, the default algorithm in basic spreadsheet software, calculates a line of best fit by minimizing the vertical distance between data points and the line.[1]

That vertical-only calculation relies on a strict assumption: the values on the x-axis must be measured without error. In clinical chemistry, the x-axis represents the existing reference assay, which always carries its own inherent measurement noise.[1][4]

"When both methods are subject to measurement error, the ordinary least-squares method underestimates the slope and overestimates the intercept," notes the MedCalc documentation on Deming regression. This regression dilution systematically flattens the trend line.[5]

If a laboratory uses ordinary least squares to compare a new assay against a reference with a 5% coefficient of variation, the resulting slope will artificially drop below the ideal 1.0. The new machine will falsely appear to under-read high patient concentrations and over-read low ones.[1][5]

Minimizing Orthogonal Distances

To correct this flattening effect, biostatisticians replace ordinary least squares with Deming regression. Originally developed in the 1940s for physics and chemistry, the Deming method acknowledges that both the x-axis and y-axis contain analytical noise.[3][5]

Instead of only measuring vertical errors, Deming regression minimizes the orthogonal, or perpendicular, distance from each data point to the fitted line. This two-dimensional optimization prevents the slope from being dragged downward by the reference assay's variance.[3][5]

The algorithm requires laboratories to input a variance ratio, often denoted as lambda. "If the two methods have the same measurement error, the variance ratio is 1," explains a 2019 SAS Institute technical review of the procedure.[3]

When the variance ratio is exactly 1.0, Deming regression simplifies into orthogonal regression. If the new test is known to be twice as precise as the old reference, the laboratory adjusts the ratio to 0.5, shifting the geometric calculation to trust the y-axis more heavily.[3][5]

However, Deming regression remains a parametric statistical method. It assumes the measurement errors in both diagnostic assays follow a normal, bell-shaped distribution, making the calculated slope highly sensitive to extreme outliers in the patient sample data.[2][5]

The Non-Parametric Alternative

Clinical blood samples frequently produce outliers due to interfering substances, hemolysis, or sample degradation. A single severely skewed data point can pull a Deming regression line off its true axis, prompting laboratories to seek a more robust mathematical alternative.[2]

In 1983, statisticians H. Passing and W. Bablok published a non-parametric regression technique designed specifically for clinical method comparison. Their algorithm ignores normal distribution requirements and actively resists the gravitational pull of extreme outliers.[2][6]

Passing-Bablok regression calculates the slope of the line connecting every possible pair of data points in the study. For a standard validation study of 100 patient samples, the software computes exactly 4,950 individual slopes.[2][6]

"The Passing and Bablok method calculates the equation of the line from the medians of all slopes," according to a methodological review in Biochemia Medica. By taking the median rather than the mean, the algorithm mathematically discards the most extreme outlier trajectories.[2]

This rank-based approach provides a highly stable estimate of proportional bias. If the median slope lands at 1.02, the laboratory knows the new assay reads exactly 2% higher than the reference across the entire clinical range, regardless of a few anomalous samples.[2][6]

Isolating Constant and Proportional Bias

Modern clinical guidelines require laboratories to evaluate both the slope and the intercept of the comparison line. The slope reveals proportional bias—errors that grow larger as the concentration of the target molecule increases.[4][6]

The y-intercept isolates constant bias, representing a flat numerical offset that affects all samples equally. An intercept of 4.0 mg/dL means the new machine consistently adds four units to every reading, often indicating a calibration blanking error.[4]

To pass regulatory validation, the ideal 1.0 slope and 0.0 intercept must fall within the 95% confidence intervals calculated by the regression software. If the confidence interval for the Passing-Bablok slope spans from 0.98 to 1.04, the proportional bias is considered statistically insignificant.[2][6]

"You can use the Passing-Bablok procedure to test whether the two methods are equivalent," notes a 2022 SAS Institute analysis. The software automatically flags any confidence interval that excludes the ideal targets, halting the deployment of miscalibrated assays.[6]

These regression techniques do not replace the Bland-Altman plot, which visualizes the absolute differences between methods. Instead, they serve as the mathematical engine for proving that a new diagnostic tool will not systematically alter patient diagnoses.[4][7]

The Danger of Correlation Coefficients

Before the widespread adoption of Deming and Passing-Bablok models, laboratories frequently misused the Pearson correlation coefficient to validate new assays. A correlation of 0.99 was widely, and incorrectly, celebrated as proof that two medical devices produced identical results.[4]

Correlation only measures the strength of a linear relationship, not the agreement between the actual values. If a new glucose meter consistently reports numbers exactly twice as high as the reference method, the Pearson correlation remains a perfect 1.0, despite the catastrophic clinical error.[4][7]

"Correlation does not mean agreement," warns the Acute Care Testing journal's guide to statistical analysis. A high correlation coefficient simply confirms that the data points form a tight line, but it reveals nothing about whether that line has the correct 1.0 slope.[4]

This mathematical distinction forced the clinical chemistry field to separate relationship testing from bias testing. Regression models quantify the exact magnitude of the bias, while correlation is now relegated to verifying that the data spans a wide enough range to make the regression valid.[4][7]

Software Standardization in Laboratories

The transition from ordinary least squares to advanced regression models required a massive overhaul of clinical laboratory software. Basic spreadsheet applications still lack native functions for Deming or Passing-Bablok calculations, forcing hospitals to adopt specialized statistical packages.[3][5]

Platforms like MedCalc and SAS now include dedicated modules for method comparison, standardizing the math across the diagnostic industry. This software automatically calculates the required variance ratios and generates the thousands of pairwise slopes needed for non-parametric analysis.[3][5][6]

Regulatory bodies now explicitly mandate these advanced regression techniques in their guidelines for method comparison. Submitting a new assay validation based on ordinary least squares is routinely rejected by accreditation inspectors reviewing hospital laboratory protocols.[7]

By acknowledging the inherent imperfection in their reference standards, clinical chemists successfully eliminated a major source of mathematical bias. The adoption of orthogonal and rank-based regression ensures that a patient's test result depends on their biology, not on a statistical artifact.[7]